Strong franc hurts Roche but cancer drugs fight back
This article was originally published in Scrip
In the first of the big pharma first-quarter earnings announcements, Roche has reported that its pharma sales have climbed 4% at constant exchange rates (-1% in Swiss francs) with continued growth of Avastin, MabThera/Rituxan, Actemra/RoActemra and Herceptin compensating for the expected decline in Xeloda sales.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.